This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458508096685v1 15/1/114    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Valentino, P Articles by Quattrone, A Search for Related Content PubMed PubMed Citation Articles by Valentino, P Articles by Quattrone, A Social Bookmarking                         What's this?

Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis

¹ Institute of Neurology, University Magna Græcia, Catanzaro, Italy;
² Institute of Neurology, University Magna Græcia, Catanzaro, Italy; Institute of Neurological Sciences, National Research Council, Mangone (CS), Italy;
³ Institute of Neurological Sciences, National Research Council, Mangone (CS), Italy
⁴ Institute of Neurology, University Magna Græcia, Catanzaro, Italy
⁵ Institute of Neurology, University Magna Græcia, Catanzaro, Italy; Institute of Neurological Sciences, National Research Council, Mangone (CS), Italy

^* To whom correspondence should be addressed.

	Abstract

Objectives

The aim of this study was to correlate the brain atrophy with serum levels of anti-GM1 antibodies in patients with relapsing–remitting multiple sclerosis (RRMS).

Methods

Plasma sample from 52 patients with RRMS and 65 healthy controls were examined for anti-GM1 antibodies. Patients with RRMS underwent to MRI study with automated method called SIENAX that calculated an estimate of gray matter (GM^V) and white matter (WM^V) volumes.

Results

The percentage of RRMS patients with increased anti-GM1 was 37.8%. Elevated levels of anti-GM1 antibodies did not correlate with brain atrophy.

Conclusions

Anti-GM1 antibodies do not represent a marker of axonal damage in patients with RRMS.

Key Words: anti-GM1, relapsing–remitting multiple sclerosis

First published on October 9, 2008, doi:10.1177/1352458508096685

Multiple Sclerosis 2009;15:114.

A more recent version of this article appeared on January 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M Podbielska and E. Hogan Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Multiple Sclerosis, September 1, 2009; 15(9): 1011 - 1029. [Abstract] [PDF]